Survival curves depicting biochemical recurrence-free survival in the radical prostatectomy (RP) and external beam radiotherapy (EBRT) groups, in (A) all (<i>P</i> <0.0001), (B) low-risk (<i>P</i> = 0.0230), (C) intermediate-risk (<i>P</i> = 0.0030), and (D) high-risk patients (<i>P</i> = 0.0025), respectively.

<p>Each <i>P</i>-value indicates the result of log-rank test.</p

Other-cause mortality in the radical prostatectomy (RP) and external beam radiotherapy (EBRT) groups (log-rank test, <i>P</i> = 0.0001).

<p>Other-cause mortality in the radical prostatectomy (RP) and external beam radiotherapy (EBRT) groups (log-rank test, <i>P</i> = 0.0001).</p

Survival curves depicting cancer-specific survival in the radical prostatectomy (RP) and external beam radiotherapy (EBRT) groups, in (A) all (<i>P</i> = 0.0010), (B) low-risk (<i>P</i> <0.0001), (C) intermediate-risk (<i>P</i> = 0.1820), and (D) high-risk patients (<i>P</i> = 0.0233), respectively.

<p>Each <i>P</i>-value indicates the result of log-rank test.</p

Baseline patient characteristics of the RP and EBRT groups in all patients (<i>n</i> = 891).

<p>RP, radical prostatectomy; EBRT, external beam radiotherapy; IQR, interquartile range; PSA, prostate-specific antigen; GS, Gleason score; ADT, androgen deprivation therapy.</p><p>*Statistically significant</p><p>^aStudent’s <i>t</i>-test</p><p>^bChi-square test.</p><p>Baseline patient characteristics of the RP and EBRT groups in all patients (<i>n</i> = 891).</p

Flow chart representing the study selection process.

<p>Flow chart representing the study selection process.</p

Baseline patient characteristics of the RP and EBRT groups in high-risk patients (<i>n</i> = 336).

<p>RP, radical prostatectomy; EBRT, external beam radiotherapy; IQR, interquartile range; PSA, prostate-specific antigen; GS, Gleason score; ADT, androgen deprivation therapy.</p><p>*Statistically significant;</p><p>^aStudent’s <i>t</i>-test;</p><p>^bChi-square test</p><p>Baseline patient characteristics of the RP and EBRT groups in high-risk patients (<i>n</i> = 336).</p